Virologic suppression among HIV-infected US Air Force members in a highly-structured programme with free access to care

被引:3
|
作者
Matthews, P. E. [1 ]
Le, T. [2 ,3 ]
Delmar, J. [1 ]
Okulicz, J. F. [1 ]
机构
[1] San Antonio Mil Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA
[2] South Texas Vet Hlth Care Syst, Vet Affairs Res Ctr, AIDS & HIV I Infect & Ctr Personalized Med, San Antonio, TX USA
[3] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA
关键词
HIV; treatment; antiretroviral therapy; HAART; AIDS; Air Force; military; continuum of care; treatment cascade; ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE; ACTIVE ANTIRETROVIRAL THERAPY; UNITED-STATES; CLINICAL-OUTCOMES; INITIAL TREATMENT; EARLY RETENTION; DOUBLE-BLIND; ENGAGEMENT; PREVENTION; HEALTH;
D O I
10.1177/0956462414563631
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The United States Air Force HIV programme has several features that may enhance antiretroviral therapy outcomes, including free access to healthcare and mandatory clinical visits every six months at a single centre. We evaluated viral load suppression (<50copies/ml) after 12 months of initial antiretroviral therapy, with extension to 18 and 24 months. Active duty Air Force members were categorised by year of antiretroviral therapy initiation: 2000-2005 (n=95, 36.1%) and 2006-2011 (n=168, 63.9%). The median months from HIV diagnosis to initial antiretroviral therapy were shorter in the 2000-2005 group (2.4, IQR 1.2-5.9) compared with the 2006-2011 group (12.6, IQR 2.6-29.0; p<0.001). Viral load suppression was greater in the 2006-2011 group compared with the 2000-2005 group at 12 months (93.2% versus 78.6%, p=0.002) and 18 months (91.8% versus 80.3%, p=0.03), and trended higher at 24 months (90.8% versus 82.5%; p=0.15). Factors associated with viral load suppression at 12 months in multivariate models included antiretroviral therapy initiation during 2006-2011 (OR 5.22, 95% CI 1.50-18.18) and CD4 count at antiretroviral therapy initiation (OR 2.29, 95% CI 1.19-14.43 per 100cells/mu l increase). Structured programmes that minimise traditional barriers to care combined with the use of contemporary antiretroviral therapy regimens can achieve clinic-wide viral load suppression in >90% of patients.
引用
下载
收藏
页码:951 / 959
页数:9
相关论文
共 50 条
  • [21] Longitudinal Associations of Syndemic Conditions with Antiretroviral Therapy Adherence and HIV Viral Suppression Among HIV-Infected Patients in Primary Care
    Satyanarayana, Satyanand
    Rogers, Brooke G.
    Bainter, Sierra A.
    Christopoulos, Katerina A.
    Fredericksen, Rob J.
    Mathews, William C.
    Moore, Richard D.
    Mugavero, Michael J.
    Napravnik, Sonia
    Carrico, Adam W.
    Mimiaga, Matthew J.
    Mayer, Kenneth H.
    Crane, Heidi M.
    Safren, Steven A.
    AIDS PATIENT CARE AND STDS, 2021, 35 (06) : 220 - 230
  • [22] Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients
    Casado, Jose L.
    Vizcarra, Pilar
    Blanco, Jose L.
    Montejano, Rocio
    Negredo, Eugenia
    Espinosa, Nuria
    Montero, Marta
    Mena, Alvaro
    Palacios, Rosario
    Lopez, Juan C.
    Vergas, Jorge
    Galindo, Maria J.
    Cabello, Alfonso
    Deltoro, Miguel Garcia
    De Santiago, Alberto Diaz
    INTERNATIONAL JOURNAL OF STD & AIDS, 2020, 31 (05) : 467 - 473
  • [23] Sexual risk behaviour and viral suppression among HIV-infected adults receiving medical care in the United States
    Mattson, Christine L.
    Freedman, Mark
    Fagan, Jennifer L.
    Frazier, Emma L.
    Beer, Linda
    Huang, Ping
    Valverde, Eduardo E.
    Johnson, Christopher
    Sanders, Catherine
    McNaghten, A. D.
    Sullivan, Patrick
    Lansky, Amy
    Mermin, Jonathan
    Heffelfinger, James
    Skarbinski, Jacek
    AIDS, 2014, 28 (08) : 1203 - 1211
  • [24] Evaluation of viral suppression and medication-related burden among HIV-infected adults in a secondary care facility
    Hedima, Erick Wesley
    Ohieku, John David
    David, Emmanuel Agada
    Ikunaiye, Nasiru Yakubu
    Nasir, Abdulrahman
    Alfa, Mustapha Ahmed
    Abubakar, Safinat
    Bwiyam, Ismaila Khalifas
    Bitrus, Tang 'an Zughumnaan
    EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY, 2024, 15
  • [25] Disparities in achieving and sustaining viral suppression among a large cohort of HIV-infected persons in care - Washington, DC
    Castel, Amanda D.
    Kalmin, Mariah M.
    Hart, Rachel L. D.
    Young, Heather A.
    Hays, Harlen
    Benator, Debra
    Kumar, Princy
    Elion, Richard
    Parenti, David
    Ruiz, Maria Elena
    Wood, Angela
    D'Angelo, Lawrence
    Rakhmanina, Natella
    Rana, Sohail
    Bryant, Maya
    Hebou, Annick
    Fernandez, Ricardo
    Abbott, Stephen
    Peterson, James
    Wood, Kathy
    Subramanian, Thilakavathy
    Binkley, Jeffrey
    Happ, Lindsey Powers
    Kharfen, Michael
    Masur, Henry
    Greenberg, Alan E.
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2016, 28 (11): : 1355 - 1364
  • [26] Postpartum Loss to HIV Care and HIV Viral Suppression among Previously Diagnosed HIV-Infected Women with a Live Birth in New York State
    Swain, Carol-Ann
    Smith, Lou C.
    Nash, Denis
    Pulver, Wendy P.
    Lazariu, Victoria
    Anderson, Bridget J.
    Warren, Barbara L.
    Birkhead, Guthrie S.
    McNutt, Louise-Anne
    PLOS ONE, 2016, 11 (08):
  • [27] Excess Clinical Comorbidity Among HIV-Infected Patients Accessing Primary Care in US Community Health Centers
    Mayer, Kenneth H.
    Loo, Stephanie
    Crawford, Phillip M.
    Crane, Heidi M.
    Leo, Michael
    DenOuden, Paul
    Houlberg, Magda
    Schmidt, Mark
    Quach, Thu
    Ruhs, Sebastian
    Vandermeer, Meredith
    Grasso, Chris
    McBurnie, Mary Ann
    PUBLIC HEALTH REPORTS, 2018, 133 (01) : 109 - 118
  • [28] Size and duration of zidovudine benefit in 1003 HIV-infected patients: US Army, Navy, and Air Force natural history data
    Gardner, LI
    Harrison, SH
    Hendrix, CW
    Blatt, SP
    Wagner, KF
    Chung, RCY
    Harris, RW
    Cohn, DL
    Burke, DS
    Mayers, DL
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 17 (04): : 345 - 353
  • [29] Risk of Active Tuberculosis in HIV-Infected Patients in Taiwan with Free Access to HIV Care and a Positive T-Spot. TB Test
    Sun, Hsin-Yun
    Hsueh, Po-Ren
    Liu, Wen-Chun
    Su, Yi-Ching
    Chang, Sui-Yuan
    Hung, Chien-Ching
    Chang, Shan-Chwen
    PLOS ONE, 2015, 10 (05):
  • [30] Drug Use and Receipt of Highly Active Antiretroviral Therapy among HIV-Infected Persons in Two US Clinic Cohorts
    McGowan, Catherine C.
    Weinstein, David D.
    Samenow, Charles P.
    Stinnette, Samuel E.
    Barkanic, Gema
    Rebeiro, Peter F.
    Sterling, Timothy R.
    Moore, Richard D.
    Hulgan, Todd
    PLOS ONE, 2011, 6 (04):